San-Antonio based company StemBiosys, Inc. (SBS) recently announced the appointment of John W. Feik as its interim CEO.
Feik previously served as a member of the Board of Directors and has worked in the pharmaceutical industry for the past 35 years. Prior to his appointment, he was President and Chief Operating Officer of DFB Pharmaceuticals, Inc.
In addition to his previous posts, Feik has been working in other sectors of the biotech market as both an investor and philanthropist, where he was involved with companies such as HealthPoint Biotherapeutics , Phyton Biotech, and StemBioSys, Inc. as well.
StemBioSys Inc. is an early-stage biomedical company focused on the isolation and expansion of adult stem cells for clinical use. “That technology and the people around it are what attracted me to invest in the company in the first place. We have great opportunities here,” he said.
For the SBS chairman, Steven A. Davis, the choice of Feik as interim CEO is the right one for this period of transition for the company, considering Feik’s business experience in the bioscience market. “His special expertise in regenerative medicine and his management skills are a huge plus for SBS as we move to target clinical applications and commercialize our innovative technologies.”
As a philanthropist, Feik has served on the private boards of the Texas BioMedical Research Institute, BioBridge Global, and the Texas Research & Technology Foundation. One of his philanthropic projects, along with his wife, has led to the establishment of a school with their name, the Feik School of Pharmacy, at the University of the Incarnate Word.
Feik will lead SBS until the company finds Savas’ substitute. Savas’ leadership was defined, according to Davis, by the strengthening of SBS technology and patents through widespread cooperation with the scientific community, and through his proven fundraising abilities.